Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma

Steven P. Rowe, Michael A. Gorin, Jennifer Gordetsky, Mark W. Ball, Phillip M. Pierorazio, Takahiro Higuchi, Jonathan I. Epstein, Mohamad E. Allaf, Mehrbod S. Javadi

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


Purpose: The differentiation of oncocytoma from renal cell carcinoma (RCC) remains a challenge with currently available cross-sectional imaging techniques. As a result, a large number of patients harboring a benign oncocytoma undergo unnecessary surgical resection. In this study, we explored the utility of 99mTc-MIBI SPECT/CT for the differentiation of these tumors based on the hypothesis that the large number of mitochondria in oncocytomas would lead to increased 99mTc-MIBI uptake. Patients andMethods: In total, 6 patients (3 with oncocytoma and 3 with RCC) were imaged with 99mTc-MIBI SPECT/CT. Relative quantification was performed by measuring tumor-to-normal renal parenchyma background ratios. Results: All 3 oncocytomas demonstrated radiotracer uptake near or above the normal renal parenchymal uptake (range of uptake ratios, 0.85-1.78). In contrast, the 3 RCCs were profoundly photopenic relative to renal background (range of uptake ratios, 0.21-0.31). Conclusions: 99mTc-MIBI SPECT/CT appears to be of value in scintigraphically distinguishing benign renal oncocytoma from RCC.

Original languageEnglish
Pages (from-to)309-313
Number of pages5
JournalClinical Nuclear Medicine
Issue number4
Publication statusPublished - Apr 21 2015
Externally publishedYes


  • Oncocytoma
  • Renal cell carcinoma
  • Tc-MIBI

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Initial experience using <sup>99m</sup>Tc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma'. Together they form a unique fingerprint.

Cite this